The American Diabetes Association (ADA), the American Association of Clinical Endocrinologists (AACE), the European Association for the Study of Diabetes (EASD), the European Society of Cardiology (ESC), and Kidney Disease: Improving Global Outcomes (KDIGO) all now recommend GLP-1 receptor agonists for glycemic control and cardiovascular risk reduction in patients with T2D with or without DKD [23,24,25,26,27,28,29]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.